Exscientia

Viva Biotech's portfolio companies achieve significant milestones: Nerio Therapeutics acquired by Boehringer Ingelheim for $1.3B; Apeiron expands investment in synthetic lethality pipeline; Full-Life Technologies licenses FL-091 to SK Biopharmaceuticals; Arthrosi doses first patient in Phase 3 trial for AR882; VivaVision enrolls first subject in VVN001 Phase III trial.

Exscientia's Q1 2024 update highlights progress in AI-driven drug design, automation, and pipeline development, including advancements in CDK7, LSD1, and MALT1 inhibitors. The company expects to save $40M annually from 2025, extending cash runway into 2027, and emphasizes partnerships and operational efficiencies.

The global biotechnology market, valued at USD 1.54 Trillion in 2023, is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95%. Growth is driven by government support, personalized medicine, COVID-19 vaccine development, agricultural biotech applications, and advancements in gene editing and synthetic biology. North America leads the market, while Asia Pacific is expected to grow the fastest.

The Global Immuno-oncology Clinical Trials Market is projected to grow from USD 6.13 billion in 2023 to USD 12.87 billion by 2030, at a CAGR of 11.17%. The report analyzes market dynamics, competitive landscape, and profiles key vendors like AstraZeneca and BioNTech. It covers market segmentation by design, phase, indication, and regional prospects including North America, Asia-Pacific, and EMEA.

The AI in Clinical Trials Market, valued at USD 1.59 Billion in 2023, is projected to reach USD 6.55 Billion by 2030, growing at a CAGR of 22.4%. AI technologies are revolutionizing clinical trials by expediting patient recruitment, optimizing trial design, and enhancing data management. North America leads the market due to its robust healthcare infrastructure and significant R&D investments. Deep learning dominates the technology segment, aiding in complex data analysis for more efficient clinical trials.

The AI in Clinical Trials Market is rapidly growing, with a projected increase from USD 1.59 billion in 2023 to USD 6.55 billion by 2030, driven by AI's role in expediting drug development, especially in oncology. Deep learning leads in technology segments, enhancing trial efficiency and precision. North America dominates the market due to its advanced healthcare infrastructure and R&D investments.

AI advancements are transforming drug discovery, with tools like AlphaFold2 enhancing protein-structure prediction. Biopharma firms are building AI capabilities through in-house expertise, acquisitions, and partnerships. Despite a decline in new AI-driven biotech companies, capital deployment has surged, with significant partnerships and some clinical trial successes. However, challenges in integration and competition persist, suggesting a future of increased M&A activity and a focus on unsaturated niches like RNA-based therapeutics.

Evotec and Exscientia used AI to develop an anticancer molecule in 8 months, a process traditionally taking 4-5 years. Exscientia's AI platform accelerates drug discovery, leading to partnerships and significant funding. AI's role in drug discovery is expanding, with companies like Recursion and BenevolentAI leveraging AI for innovative treatments and collaborations with pharma giants.